Addus HomeCare (ADUS)

Market Price (9/23/2026): $114.1 | Market Cap: $2.1 BilSector: Health Care | Industry: Health Care Services

Addus HomeCare (ADUS)

Market Price (9/23/2026): $114.1
Market Cap: $2.1 Bil
Sector: Health Care
Industry: Health Care Services

Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.

Attractive yield
Total YieldTotal Yield = Earnings Yield + Dividend Yield, Earnings Yield = Net Income / Market Cap Dividend Yield = Total Dividends / Market Cap is 5.0%, FCF Yield is 7.4%

Attractive cash flow generation
CFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is 11%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is 10%

Low stock price volatility
Vol 12M is 29%

Megatrend and thematic drivers
Megatrends include Aging Population & Chronic Disease, and Digital Health & Telemedicine. Themes include Geriatric Care, Remote Patient Monitoring, Show more.

Weak multi-year price returns
2Y Excs Rtn is -52%, 3Y Excs Rtn is -38%

Key risks
ADUS key risks include [1] the potential failure to successfully integrate acquisitions and achieve anticipated synergies from its M&A-focused growth strategy.

0	Attractive yield Total YieldTotal Yield = Earnings Yield + Dividend Yield, Earnings Yield = Net Income / Market Cap Dividend Yield = Total Dividends / Market Cap is 5.0%, FCF Yield is 7.4%
1	Attractive cash flow generation CFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is 11%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is 10%
2	Low stock price volatility Vol 12M is 29%
3	Megatrend and thematic drivers Megatrends include Aging Population & Chronic Disease, and Digital Health & Telemedicine. Themes include Geriatric Care, Remote Patient Monitoring, Show more.
4	Weak multi-year price returns 2Y Excs Rtn is -52%, 3Y Excs Rtn is -38%
5	Key risks ADUS key risks include [1] the potential failure to successfully integrate acquisitions and achieve anticipated synergies from its M&A-focused growth strategy.

ADUS in ETFs

Weight = ADUS's share of each fund

VTI0.00%

ITOT0.00%

IWM0.07%

IJR0.13%

IHF0.31%

SLYG0.17%

IJT0.15%

SLYV0.08%

+13 more covered ETFs

Valuation & Metrics

FYE: 12/31	Forward FYE		Now	Historical (CYE & TTM)
	2027	2026	9/23/26	2025	2024	2023	2022
Share Price			$114.10	$107.39	$125.35	$92.85	$99.49
Mkt Cap ($ Bil)			2.1	1.9	2.2	1.5	1.6
+ Debt ($ Bil)			0.1	0.2	0.3	0.2	0.2
- Cash ($ Bil)			0.1	0.1	0.1	0.1	0.1
TEV ($ Bil)			2.1	2.1	2.5	1.7	1.8
Valuation Ratios
P/S	1.3	1.4	1.4	1.4	1.9	1.4	1.7
P/EBIT	10.7	11.4	13.9	13.8	21.0	16.1	22.9
P/E	14.9	16.0	19.8	20.3	30.5	23.8	34.4
P/FCF	—	—	13.5	18.7	20.3	14.5	16.3
Sector Ratios (* = sector average)
P/S *			4.1	4.0	3.9	4.2	4.5
P/EBIT *			-1.9	-1.7	-1.4	-1.5	-1.3
P/E *			-1.8	-1.8	-1.6	-1.8	-1.3
P/FCF *			-1.9	-1.8	-1.4	-1.6	-1.6

FYE: 12/31	Forward FYE		Now
	2027	2026	9/23/26
Share Price			$114.10
Mkt Cap ($ Bil)			2.1
+ Debt ($ Bil)			0.1
- Cash ($ Bil)			0.1
TEV ($ Bil)			2.1
Valuation Ratios
P/S	1.3	1.4	1.4
P/EBIT	10.7	11.4	13.9
P/E	14.9	16.0	19.8
P/FCF	—	—	13.5
Sector Ratios (* = sector average)
P/S *			4.1
P/EBIT *			-1.9
P/E *			-1.8
P/FCF *			-1.9

FYE: 12/31	ADUS [1]	S&P 500 [2]
REVENUE GROWTH
LTM Revenue [3]	$1.5 Bil	—
FY 2026 Sales	$1.5 Bil	—
FY 2027 Sales	$1.6 Bil	—
FY 2026 Sales Growth	3.2%	—
FY 2027 Sales Growth	4.9%	12.8%
EARNINGS
LTM Net Income (GAAP) [3]	$105.3 Mil	—
FY 2026 Net Income (Non-GAAP)	$130.5 Mil	—
FY 2027 Net Income (Non-GAAP)	$140.1 Mil	—
FY 2027 Net Income Growth	7.4%	18.0%
FY 2026 EPS (Non-GAAP)	$7.05	—
FY 2027 EPS (Non-GAAP)	$7.51	—
FY 2027 EPS Growth	6.6%	—
VALUATION
FY 2026 P/S	1.4	1.6
FY 2027 P/S	1.3	—
FY 2026 P/E	16.0	7.5
FY 2027 P/E	14.9	—

[1] ADUS forward figures are analyst consensus for the next two fiscal years (fiscal year end 12/31). Net Income and EPS are non-GAAP (adjusted) consensus. P/S and P/E divide the current market cap by the consensus figure.
[2] S&P 500 figures are the SPY ETF's holdings-weighted forward aggregate. P/S and P/E reflect FY1/FY2 consensus blended to the 12-month window ending 9/30/27 (~one year forward), shown when ≥90% of index weight has estimates. Growth is the aggregate next-fiscal-year vs current-fiscal-year (FY1→FY2) change. Index-level dollar Sales, Net Income and EPS are not applicable.
[3] LTM = reported trailing-twelve-month actuals (GAAP).

	ADUS	S&P 500
REVENUE GROWTH	GOOD
Rev LTM ($ Bil)	1.5
Rev Chg Q	8.0%	9.3%
Rev Chg LTM	15.9%	8.3%
Rev Chg 3Y Avg	13.9%	5.8%
PROFITABILITY	FAIR
Op Inc LTM ($ Bil)	0.1
CFO LTM ($ Bil)	0.2
Net Inc LTM ($ Bil)	0.1
Op Mgn LTM	10.0%	18.6%
CFO/Rev LTM	11.0%	21.8%
Net Inc Mgn	7.1%	13.1%
VALUATION	LOW
P/S	1.4	3.1
P/CFO	12.9	14.7
P/FCF	13.5	19.3
P/E	19.8	22.6
STABILITY	GOOD
Debt/Equity	0.05	0.21
Cash/Assets	0.07	0.07

AI Analysis | Feedback

Metric	Value	Date	Source
Number of Consumers	approximately 62,000	11052025	Link
Number of Locations	265	11052025	Link
Number of States of Operation	23	11052025	Link
Personal Care Same-Store Revenue Growth	7.4%	6302025	Link
Personal Care Same-Store Hours Increase	1.6%	6302025	Link
Sales Volumes Year-on-Year Growth	33.9%	9302025	Link

Price Chart

No Events

Why The Stock Moved

Qualitative Assessment

AI Analysis | Feedback

Updated on 9/22/2026

Addus HomeCare (ADUS) stock has gained about 25% since 5/31/2026 because of the following key factors:

1. Strong financial performance in fiscal Q2 2026 exceeded analyst expectations.

Addus HomeCare reported adjusted earnings per share (EPS) of $1.73 for the fiscal second quarter ended June 30, 2026, surpassing the consensus estimate of $1.70 by $0.03. Additionally, quarterly revenue increased by 8.0% year-over-year to $377.41 million, exceeding analysts' expectations of $376.24 million. Adjusted EBITDA also rose by 11.9% year-over-year to $49.2 million.

2. Announcement of a significant strategic acquisition poised to expand revenue.

On September 14, 2026, Addus HomeCare announced a definitive agreement to acquire the personal care division of AccentCare for approximately $275 million. This acquisition is projected to add roughly $280 million in annualized personal care revenue, representing an approximate 19% increase to Addus' current revenue base, and is expected to be accretive to financial results.

Show more

Holding a concentrated position? Know your true downside before the momentum shifts.

Protect Your Wealth →

Stock Movement Drivers

Fundamental Drivers

The 24.6% change in ADUS stock from 5/31/2026 to 9/22/2026 was primarily driven by a 18.7% change in the company's P/E Multiple.

(LTM values as of)	5312026	9222026	Change
Stock Price ($)	91.68	114.24	24.6%
Change Contribution By:
Total Revenues ($ Mil)	1,448	1,476	1.9%
Net Income Margin (%)	6.9%	7.1%	3.6%
P/E Multiple	16.7	19.8	18.7%
Shares Outstanding (Mil)	18	18	-0.5%
Cumulative Contribution			24.6%

LTM = Last Twelve Months as of date shown

Market Drivers

5/31/2026 to 9/22/2026

	Return	Correlation
ADUS	24.6%
Market (SPY)	2.5%	-10.7%
Sector (XLV)	14.2%	41.3%

Fundamental Drivers

The 10.3% change in ADUS stock from 2/28/2026 to 9/22/2026 was primarily driven by a 5.8% change in the company's Net Income Margin (%).

(LTM values as of)	2282026	9222026	Change
Stock Price ($)	103.53	114.24	10.3%
Change Contribution By:
Total Revenues ($ Mil)	1,423	1,476	3.8%
Net Income Margin (%)	6.7%	7.1%	5.8%
P/E Multiple	19.6	19.8	1.5%
Shares Outstanding (Mil)	18	18	-0.9%
Cumulative Contribution			10.3%

LTM = Last Twelve Months as of date shown

Market Drivers

2/28/2026 to 9/22/2026

	Return	Correlation
ADUS	10.3%
Market (SPY)	13.3%	4.5%
Sector (XLV)	7.0%	32.2%

Fundamental Drivers

The -0.8% change in ADUS stock from 8/31/2025 to 9/22/2026 was primarily driven by a -20.8% change in the company's P/E Multiple.

(LTM values as of)	8312025	9222026	Change
Stock Price ($)	115.17	114.24	-0.8%
Change Contribution By:
Total Revenues ($ Mil)	1,274	1,476	15.9%
Net Income Margin (%)	6.5%	7.1%	9.5%
P/E Multiple	25.0	19.8	-20.8%
Shares Outstanding (Mil)	18	18	-1.4%
Cumulative Contribution			-0.8%

LTM = Last Twelve Months as of date shown

Market Drivers

8/31/2025 to 9/22/2026

	Return	Correlation
ADUS	-0.8%
Market (SPY)	21.2%	10.7%
Sector (XLV)	25.8%	28.5%

Fundamental Drivers

The 30.3% change in ADUS stock from 8/31/2023 to 9/22/2026 was primarily driven by a 47.8% change in the company's Total Revenues ($ Mil).

(LTM values as of)	8312023	9222026	Change
Stock Price ($)	87.70	114.24	30.3%
Change Contribution By:
Total Revenues ($ Mil)	999	1,476	47.8%
Net Income Margin (%)	5.4%	7.1%	32.4%
P/E Multiple	26.1	19.8	-23.9%
Shares Outstanding (Mil)	16	18	-12.5%
Cumulative Contribution			30.3%

LTM = Last Twelve Months as of date shown

Market Drivers

8/31/2023 to 9/22/2026

	Return	Correlation
ADUS	30.3%
Market (SPY)	78.3%	26.1%
Sector (XLV)	34.1%	28.7%

Return vs. Risk

Price Returns Compared

	2021	2022	2023	2024	2025	2026	Total [1]
Returns
ADUS Return	-20%	6%	-7%	35%	-14%	7%	-1%
Peers Return	15%	-18%	72%	21%	50%	21%	255%
S&P 500 Return	27%	-19%	24%	23%	16%	13%	107%
Monthly Win Rates [3]
ADUS Win Rate	33%	50%	50%	67%	58%	56%
Peers Win Rate	50%	42%	62%	58%	55%	58%
S&P 500 Win Rate	75%	42%	67%	75%	67%	56%
Max Drawdowns [4]
ADUS Max Drawdown	-43%	-25%	-31%	-12%	-34%	-25%
Peers Max Drawdown	-25%	-50%	-23%	-25%	-30%	-32%
S&P 500 Max Drawdown	-5%	-25%	-10%	-8%	-19%	-9%

[1] Cumulative total returns since the beginning of 2021
[2] Peers: ENSG, AVAH, CHE, BTSG, OPCH. See ADUS Returns vs. Peers.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2026 data is for the year up to 9/22/2026 (YTD)

Event	ADUS	S&P 500
2025 US Tariff Shock
% Loss	-20.7%	-18.8%
% Gain to Breakeven	26.0%	23.1%
Time to Breakeven	67 days	79 days
Summer-Fall 2023 Five Percent Yield Shock
% Loss	-13.6%	-9.5%
% Gain to Breakeven	15.7%	10.5%
Time to Breakeven	34 days	24 days
2023 SVB Regional Banking Crisis
% Loss	-24.4%	-6.7%
% Gain to Breakeven	32.2%	7.1%
Time to Breakeven	370 days	31 days
2022 Inflation Shock & Fed Tightening
% Loss	-24.8%	-24.5%
% Gain to Breakeven	32.9%	32.4%
Time to Breakeven	148 days	427 days
2020 COVID-19 Crash
% Loss	-51.4%	-33.7%
% Gain to Breakeven	105.9%	50.9%
Time to Breakeven	139 days	140 days
2015-2016 China Devaluation / Global Growth Scare
% Loss	-42.6%	-12.2%
% Gain to Breakeven	74.3%	13.9%
Time to Breakeven	236 days	62 days

Compare to ENSG, AVAH, CHE, BTSG, OPCH

In The Past

Addus HomeCare's stock fell -20.7% during the 2025 US Tariff Shock. Such a loss loss requires a 26.0% gain to breakeven.

Preserve Wealth

Limiting losses and compounding gains is essential to preserving wealth.

Asset Allocation

Actively managed asset allocation strategies protect wealth. Learn more.

Event	ADUS	S&P 500
2025 US Tariff Shock
% Loss	-20.7%	-18.8%
% Gain to Breakeven	26.0%	23.1%
Time to Breakeven	67 days	79 days
2023 SVB Regional Banking Crisis
% Loss	-24.4%	-6.7%
% Gain to Breakeven	32.2%	7.1%
Time to Breakeven	370 days	31 days
2022 Inflation Shock & Fed Tightening
% Loss	-24.8%	-24.5%
% Gain to Breakeven	32.9%	32.4%
Time to Breakeven	148 days	427 days
2020 COVID-19 Crash
% Loss	-51.4%	-33.7%
% Gain to Breakeven	105.9%	50.9%
Time to Breakeven	139 days	140 days
2015-2016 China Devaluation / Global Growth Scare
% Loss	-42.6%	-12.2%
% Gain to Breakeven	74.3%	13.9%
Time to Breakeven	236 days	62 days
2014-2016 Oil Price Collapse
% Loss	-21.0%	-6.8%
% Gain to Breakeven	26.6%	7.3%
Time to Breakeven	50 days	15 days
2011 US Debt Ceiling Crisis & European Contagion
% Loss	-44.8%	-17.9%
% Gain to Breakeven	81.1%	21.8%
Time to Breakeven	399 days	123 days

Compare to ENSG, AVAH, CHE, BTSG, OPCH

In The Past

Addus HomeCare's stock fell -20.7% during the 2025 US Tariff Shock. Such a loss loss requires a 26.0% gain to breakeven.

Preserve Wealth

Limiting losses and compounding gains is essential to preserving wealth.

Asset Allocation

Actively managed asset allocation strategies protect wealth. Learn more.

About Addus HomeCare (ADUS)

Business Description Analogies Products Customers Suppliers Management Key Risks Emerging Threats Market Size Revenue Drivers Capital Allocation

Addus HomeCare Corporation (ADUS) is a leading provider of comprehensive in-home healthcare services across the United States. The company's core mission is to support elderly, chronically ill, or disabled individuals, as well as those who are terminally ill, by delivering essential care in their homes. This approach helps these individuals maintain independence, improve their quality of life, and often prevents the need for hospitalization or institutionalization. Addus operates through three primary segments, each addressing distinct needs within the homecare spectrum.

The company's main services include Personal Care, Hospice, and Home Health. The Personal Care segment offers non-medical assistance with daily living activities, such as bathing, grooming, meal preparation, medication reminders, housekeeping, and transportation. The Hospice segment focuses on providing palliative nursing care, social work, spiritual counseling, and bereavement support for terminally ill individuals and their families. Lastly, the Home Health segment delivers skilled nursing care along with physical, occupational, and speech therapy services for individuals recovering from illness or hospitalization.

Addus HomeCare serves a diverse client base, including federal, state, and local governmental agencies, managed care organizations, and commercial insurers, as well as private individuals who pay for services directly. The company's extensive network spans 22 states, where it operates through 206 offices, allowing it to provide vital care to a broad population across various regions of the country.

AI Analysis | Feedback

Think of Addus HomeCare as **Home Instead Senior Care**, but also offering professional medical home health and hospice services.

Imagine it like **Teladoc or MDLive**, but for a broad range of in-person home care services, including personal assistance, skilled nursing, and hospice.

Consider it like **Uber or Lyft**, but for dispatching trained caregivers and nurses directly to people's homes to provide a spectrum of personal, medical, and hospice care services.

AI Analysis | Feedback

```html

Personal Care Services: Provides non-medical assistance with daily living activities such as bathing, grooming, feeding, medication reminders, meal preparation, housekeeping, and transportation.
Hospice Services: Offers palliative nursing care, social work, spiritual counseling, homemaker, and bereavement counseling for terminally ill individuals and their families.
Home Health Services: Delivers skilled nursing and physical, occupational, and speech therapy for individuals requiring assistance during an illness or after hospitalization.

```

AI Analysis | Feedback

Addus HomeCare (ADUS) primarily serves individuals who require assistance with daily living, palliative care, or skilled nursing and therapy during illness or post-hospitalization. Based on the company's description of who it provides services to, its major customers fall into the following categories:

Elderly persons
Chronically ill persons
Disabled persons

AI Analysis | Feedback

null

AI Analysis | Feedback

Dirk Allison, Chairman and Chief Executive Officer

Dirk Allison joined Addus HomeCare as President and Chief Executive Officer in January 2016 and was named Chairman of the Board and Chief Executive Officer in March 2021, having served on its board of directors since 2010. He brings over 29 years of leadership experience in various healthcare segments. His prior roles include President and CEO of Correctional Healthcare Companies, Inc. from 2013 to 2014, and President and CEO of CCS Medical, Inc. from 2011 to 2013. Earlier, he was Senior Vice President, Chief Financial Officer, and Treasurer of Odyssey Healthcare, Inc., which was acquired by Gentiva Health Services, Inc. in 2010. He also held executive finance positions at Omniflight, Inc., Ardent Health Services LLC, and Renal Care Group, Inc., and served as President and CEO of several publicly and privately held companies between 1987 and 1999. His experience includes leadership at Oceans Healthcare, a private equity-backed behavioral healthcare provider, indicating a pattern of managing companies with private equity backing.

Brian Poff, Executive Vice President and Chief Financial Officer

Brian Poff became Executive Vice President and Chief Financial Officer in May 2016, bringing over 16 years of accounting and finance experience primarily in public and private healthcare organizations. Prior to Addus, he was Chief Financial Officer and Treasurer of Oceans Healthcare, a private equity-backed behavioral health care provider. He also served as Senior Vice President of Finance and Chief Accounting Officer for CCS Medical, Corporate Controller for AccentCare, Inc., and Division Chief Financial Officer for Hospice Services at Gentiva Health Services. Poff was Assistant Controller for Odyssey HealthCare, Inc., which was acquired by Gentiva Health Services, and Controller for Horizon Health Corporation until its acquisition by Psychiatric Solutions, Inc. His background includes managing companies with private equity backing.

Heather Dixon, President and Chief Operating Officer

Heather Dixon was appointed President and Chief Operating Officer in September 2025. A Certified Public Accountant, she previously served as Chief Financial Officer of Acadia Healthcare and held positions as Chief Financial Officer and interim Chief Operating Officer at Everside Health. Her career also includes senior leadership roles as Senior Vice President, Global Controller and Chief Accounting Officer for Walgreens Boots Alliance, Inc. and Vice President, Controller and Chief Accounting Officer for Aetna. She began her professional career at PricewaterhouseCoopers and served as an independent board member of Signify Health until its acquisition by CVS Health in March 2023.

Darby Anderson, Executive Vice President and Chief Government Relations Officer

Darby Anderson joined Addus HomeCare in 1996 as Midwest Regional Manager, progressing to Regional Vice President of Midwest/East in 2000, and serving as Senior Vice President until December 2014. He is currently Executive Vice President and Chief Government Relations Officer. Anderson has also held board and advisory committee positions, including with the Older Adult Services Advisory Committee and the Community Care Program Advisory Committee in Illinois.

Sean Gaffney, Executive Vice President and Chief Legal Officer

Sean Gaffney became Executive Vice President and Chief Legal Officer of Addus HomeCare in April 2019. Before joining Addus, he served as General Counsel at Encompass Health – Home Health & Hospice. Prior to that, he was Executive Vice President of Corporate Development, General Counsel, and Secretary of BroadJump, LLC, a software start-up.

AI Analysis | Feedback

The key risks to Addus HomeCare's (ADUS) business are primarily rooted in the evolving healthcare regulatory landscape, persistent workforce challenges, and intense market competition.

Regulatory Changes and Reimbursement Pressures: Addus HomeCare relies significantly on government-funded programs like Medicaid and Medicare for a substantial portion of its revenue. Consequently, the company is highly susceptible to changes in government policies, funding levels, and reimbursement models. A prominent example is the Medicaid Access Rule, which mandates that 80% of funds be spent on compensation, posing a risk to the company's margins if reimbursement rates do not increase to offset these costs. Shifts in policy and potential cuts to government healthcare programs could compress Addus's margins and affect its revenue streams.
Workforce Shortages and Wage Inflation: The home healthcare industry, in which Addus operates, faces a significant and ongoing challenge with caregiver recruitment and retention. This shortage leads to increased wage inflation and high turnover rates, directly impacting Addus's operating costs and gross margins, as it is a labor-intensive business. The difficulty in finding and keeping qualified staff can also limit the company's capacity to meet growing demand and expand services.
Increased Competition and Managed Care Organization Dynamics: The home care services market is highly competitive, with many providers vying for market share. Addus HomeCare's increasing reliance on Managed Care Organizations (MCOs) as payor clients also presents a risk. This shift can potentially reduce Addus's bargaining power, leading to lower negotiated rates and increased pressure on profitability and growth.

AI Analysis | Feedback

null

AI Analysis | Feedback

Addus HomeCare (symbol: ADUS) operates in the U.S. market across three main segments: Personal Care, Hospice, and Home Health. The addressable markets for these services are sized as follows:

Personal Care: The U.S. personal care services market was valued at approximately USD 455.13 billion in 2025. This market is driven by factors such as the increasing aging population, which requires services to maintain independence and support daily living activities.
Hospice: The U.S. hospice market was estimated at USD 29.92 billion in 2024. This market is projected to grow to USD 39.09 billion by 2030, driven by the rising prevalence of chronic diseases among the geriatric population and the increasing need for quality end-of-life care at home.
Home Health: The U.S. home healthcare services market size was valued at USD 100.95 billion in 2024. This market is projected to grow to USD 176.30 billion by 2032, with nursing care dominating due to the increasing demand for skilled nursing care at home, particularly among the geriatric population.

AI Analysis | Feedback

Addus HomeCare Corporation (ADUS) is expected to experience future revenue growth over the next two to three years driven by several key factors:

Organic Growth in Personal Care and Hospice Segments: Addus anticipates continued organic expansion within its Personal Care and Hospice segments. The Personal Care segment is expected to benefit from increased service volumes and a rise in authorized hours served, with the impact of Medicaid redeterminations in states like Illinois nearing its conclusion. The Hospice segment is also poised for growth through higher admissions, an increased average daily census, and improved revenue per patient day.
State-Mandated Rate Increases: Favorable reimbursement rate increases, particularly in significant markets such as Illinois and Texas, are identified as a direct contributor to revenue growth. These rate adjustments improve the revenue generated per service provided.
Strategic Acquisitions: Addus HomeCare has a proven track record of growth through strategic acquisitions, and management has indicated plans to continue pursuing selective acquisitions in 2026. The company's strong financial position is expected to support these bolt-on deals, contributing to both market density and expansion into new areas.
Growing Demand for Home-Based Care: The fundamental demographic trend of an aging population, coupled with a societal preference for in-home care due to its value and cost-efficiency compared to institutional settings, is a sustained driver of demand for Addus's services across its segments.
Improved Labor Market Conditions: A softening labor market, especially in key operational states such as Illinois, is expected to alleviate caregiver shortages. This increased availability of workers can enable Addus to serve a greater number of authorized hours and clients, thereby driving volume-based revenue growth.

AI Analysis | Feedback

Share Repurchases

Addus HomeCare completed a $250.0 million stock repurchase in 2024.

Share Issuance

In June 2024, Addus HomeCare raised $175.6 million through a public offering of 1,725,000 shares of common stock at $108.00 per share.
The net proceeds from this offering were intended for the repayment of outstanding indebtedness under its credit facility and for general corporate purposes, including future acquisitions.

Outbound Investments

In December 2024, Addus HomeCare completed the acquisition of the personal care operations of Gentiva for approximately $350 million, expanding its market coverage in seven states and entering Texas and Missouri as new markets.
During 2023, Addus HomeCare acquired Tennessee Quality Care for $106 million and also acquired Coastal Nursecare of Florida, Inc.
In 2022, the company purchased Illinois-based hospice provider JourneyCare Inc. for $85 million and acquired Chicago-based Apple Home Health Ltd.

Capital Expenditures

Addus HomeCare continues to invest in technologies that support its operations and enhance the work of its caregivers.
The company's capital expenditures for environmental matters were not material during the year ended December 31, 2024.

Interactive Breakdown

null

null

Better Bets vs. Addus HomeCare (ADUS)

INDUSTRY: Health Care Services

Higher Rev Chg 3Y Avg | Lower P/S (Values for ADUS: 13.9% | 1.4x)

CI (131.9% | 0.3x)

Cigna

BTSG (21.9% | 0.8x)

BrightSpring Health Services

PRVA (16.2% | 1.0x)

Privia Health

ALHC (41.4% | 0.4x)

Alignment Healthcare

Higher Rev Chg 3Y Avg | Lower P/Op Inc (Values for ADUS: 13.9% | 14.1x)

CI (131.9% | 8.1x)

Cigna

Higher Rev Chg LTM (Value for ADUS: 15.9%)

HIMS (28.0%)

Hims & Hers Health

BTSG (26.4%)

BrightSpring Health Services

LFST (20.4%)

LifeStance Health

RDNT (18.9%)

RadNet

VCYT (17.3%)

Veracyte

Higher Rev Chg 3Y Avg (Value for ADUS: 13.9%)

CI (131.9%)

Cigna

HIMS (55.6%)

Hims & Hers Health

BTSG (21.9%)

BrightSpring Health Services

LFST (18.3%)

LifeStance Health

RDNT (14.1%)

RadNet

Higher Op Mgn LTM (Value for ADUS: 10.0%)

SHC (32.8%)

Sotera Health

DVA (14.9%)

DaVita

DGX (14.1%)

Quest Diagnostics

CHE (13.6%)

Chemed

LH (11.4%)

Labcorp

Higher CFO/Rev LTM (Value for ADUS: 11.0%)

DGX (16.5%)

Quest Diagnostics

DVA (15.7%)

DaVita

CHE (15.0%)

Chemed

RDNT (13.7%)

RadNet

LH (11.4%)

Labcorp

Higher FCF/Rev LTM (Value for ADUS: 10.5%)

CHE (12.5%)

Chemed

CON (11.7%)

Concentra Parent

DGX (11.7%)

Quest Diagnostics

DVA (11.5%)

DaVita

LFST (11.0%)

LifeStance Health

Higher Total Yield (Value for ADUS: 5.0%)

CI (11.2%)

Cigna

CVS (7.5%)

CVS Health

DVA (7.1%)

DaVita

DGX (5.5%)

Quest Diagnostics

CON (5.3%)

Concentra Parent

SECTOR: Health Care

Higher Rev Chg 3Y Avg | Lower P/S (Values for ADUS: 13.9% | 1.4x)

CI (131.9% | 0.3x)

Cigna

BTSG (21.9% | 0.8x)

BrightSpring Health Services

OSCR (44.8% | 0.6x)

Oscar Health

PRVA (16.2% | 1.0x)

Privia Health

CLOV (2494.5% | 1.0x)

Clover Health Investments

Higher Rev Chg 3Y Avg | Lower P/Op Inc (Values for ADUS: 13.9% | 14.1x)

CI (131.9% | 8.1x)

Cigna

INCY (18.5% | 13.8x)

Incyte

HRMY (24.5% | 10.4x)

Harmony Biosciences

ADMA (36.8% | 10.3x)

ADMA Biologics

ANIP (34.6% | 12.6x)

ANI Pharmaceuticals

Higher Rev Chg LTM (Value for ADUS: 15.9%)

LLY (49.6%)

Eli Lilly

NTRA (37.8%)

Natera

ISRG (20.7%)

Intuitive Surgical

HUM (18.3%)

Humana

BDX (17.4%)

Becton Dickinson

Higher Rev Chg 3Y Avg (Value for ADUS: 13.9%)

CI (131.9%)

Cigna

NTRA (42.8%)

Natera

LLY (39.4%)

Eli Lilly

ISRG (18.4%)

Intuitive Surgical

BSX (16.2%)

Boston Scientific

Higher Op Mgn LTM (Value for ADUS: 10.0%)

LLY (49.7%)

Eli Lilly

ABBV (33.9%)

AbbVie

JNJ (26.8%)

Johnson & Johnson

TMO (18.3%)

Thermo Fisher Scientific

MRK (10.5%)

Merck

Higher CFO/Rev LTM (Value for ADUS: 11.0%)

LLY (35.3%)

Eli Lilly

ABBV (30.3%)

AbbVie

MRK (30.0%)

Merck

JNJ (28.2%)

Johnson & Johnson

TMO (19.5%)

Thermo Fisher Scientific

Higher FCF/Rev LTM (Value for ADUS: 10.5%)

ABBV (28.3%)

AbbVie

MRK (24.1%)

Merck

JNJ (22.7%)

Johnson & Johnson

LLY (17.0%)

Eli Lilly

TMO (15.8%)

Thermo Fisher Scientific

Higher Total Yield (Value for ADUS: 5.0%)

PFE (8.9%)

Pfizer

UNH (6.6%)

UnitedHealth

AMGN (6.3%)

Amgen

ABT (5.4%)

Abbott Laboratories

JNJ (5.2%)

Johnson & Johnson

All Other Sectors

Higher Rev Chg 3Y Avg | Lower P/S (Values for ADUS: 13.9% | 1.4x)

PGR (17.8% | 1.3x)

Progressive

ENB (23.1% | 1.3x)

Enbridge

MFC (15.0% | 1.3x)

Manulife Financial

CCL (23.1% | 1.1x)

Carnival Corporation

CPNG (17.3% | 0.7x)

Coupang

Higher Rev Chg 3Y Avg | Lower P/Op Inc (Values for ADUS: 13.9% | 14.1x)

NEM (32.1% | 9.5x)

Newmont

ENB (23.1% | 9.2x)

Enbridge

AEM (34.4% | 12.0x)

Agnico Eagle Mines

CP (15.9% | 13.7x)

Canadian Pacific Kansas City

B (25.3% | 6.8x)

Barrick Mining

Higher Rev Chg LTM (Value for ADUS: 15.9%)

MU (167.0%)

Micron Technology

NVDA (83.4%)

NVIDIA

META (27.7%)

Meta Platforms

GOOGL (20.1%)

Alphabet

MSFT (17.8%)

Microsoft

Higher Rev Chg 3Y Avg (Value for ADUS: 13.9%)

NVDA (116.5%)

NVIDIA

MU (80.9%)

Micron Technology

META (23.8%)

Meta Platforms

MSFT (16.1%)

Microsoft

GOOGL (15.5%)

Alphabet

Higher Op Mgn LTM (Value for ADUS: 10.0%)

NVDA (65.2%)

NVIDIA

MSFT (46.8%)

Microsoft

AAPL (33.2%)

Apple

GOOGL (33.1%)

Alphabet

AMZN (12.1%)

Amazon.com

Higher CFO/Rev LTM (Value for ADUS: 11.0%)

MSFT (55.1%)

Microsoft

NVDA (44.3%)

NVIDIA

GOOGL (41.6%)

Alphabet

AAPL (31.4%)

Apple

AMZN (20.8%)

Amazon.com

Higher FCF/Rev LTM (Value for ADUS: 10.5%)

NVDA (41.9%)

NVIDIA

AAPL (29.3%)

Apple

MSFT (20.2%)

Microsoft

META (18.0%)

Meta Platforms

GOOGL (11.9%)

Alphabet

Higher Total Yield (Value for ADUS: 5.0%)

BAC (10.8%)

Bank of America

JPM (9.0%)

JPMorgan Chase

BRK-B (7.9%)

Berkshire Hathaway

XOM (7.5%)

ExxonMobil

GOOGL (6.0%)

Alphabet

Best Bets in Health Care

What You Pay

P/EBIT (Value for ADUS: 13.9x)

VEEV (40.9x)

Veeva Systems

DOCS (24.9x)

Doximity

HALO (22.4x)

Halozyme Therapeutics

HRMY (9.4x)

Harmony Biosciences

BMY (9.3x)

Bristol-Myers Squibb

ZTS (8.7x)

Zoetis

NBIX (17.6x)

Neurocrine Biosciences

PBH (8.1x)

Prestige Consumer Healthcare

ADMA (9.9x)

ADMA Biologics

LGND (24.5x)

Ligand Pharmaceuticals

P/E (Value for ADUS: 19.8x)

VEEV (41.7x)

Veeva Systems

DOCS (29.0x)

Doximity

HALO (32.6x)

Halozyme Therapeutics

HRMY (13.3x)

Harmony Biosciences

BMY (13.7x)

Bristol-Myers Squibb

ZTS (11.6x)

Zoetis

NBIX (20.4x)

Neurocrine Biosciences

PBH (13.2x)

Prestige Consumer Healthcare

ADMA (13.3x)

ADMA Biologics

LGND (30.4x)

Ligand Pharmaceuticals

What You Get

Rev Chg 3Y Avg (Value for ADUS: 13.9%)

VEEV (15.7%)

Veeva Systems

DOCS (14.5%)

Doximity

HALO (29.7%)

Halozyme Therapeutics

HRMY (24.5%)

Harmony Biosciences

BMY (2.9%)

Bristol-Myers Squibb

ZTS (5.0%)

Zoetis

NBIX (26.5%)

Neurocrine Biosciences

PBH (-0.7%)

Prestige Consumer Healthcare

ADMA (36.8%)

ADMA Biologics

LGND (23.2%)

Ligand Pharmaceuticals

Rev Chg LTM (Value for ADUS: 15.9%)

VEEV (16.5%)

Veeva Systems

DOCS (11.2%)

Doximity

HALO (41.2%)

Halozyme Therapeutics

HRMY (24.3%)

Harmony Biosciences

BMY (3.1%)

Bristol-Myers Squibb

ZTS (1.5%)

Zoetis

NBIX (34.4%)

Neurocrine Biosciences

PBH (-1.4%)

Prestige Consumer Healthcare

ADMA (8.0%)

ADMA Biologics

LGND (54.9%)

Ligand Pharmaceuticals

Rev Chg Q (Value for ADUS: 8.0%)

VEEV (17.6%)

Veeva Systems

DOCS (7.3%)

Doximity

HALO (47.7%)

Halozyme Therapeutics

HRMY (30.3%)

Harmony Biosciences

BMY (5.7%)

Bristol-Myers Squibb

ZTS (-0.2%)

Zoetis

NBIX (39.5%)

Neurocrine Biosciences

PBH (6.5%)

Prestige Consumer Healthcare

ADMA (2.0%)

ADMA Biologics

LGND (33.7%)

Ligand Pharmaceuticals

FCF/Rev 3Y Avg (Value for ADUS: 8.9%)

VEEV (44.1%)

Veeva Systems

DOCS (42.3%)

Doximity

HALO (41.3%)

Halozyme Therapeutics

HRMY (34.3%)

Harmony Biosciences

BMY (27.2%)

Bristol-Myers Squibb

ZTS (24.0%)

Zoetis

NBIX (23.4%)

Neurocrine Biosciences

PBH (22.4%)

Prestige Consumer Healthcare

ADMA (18.8%)

ADMA Biologics

LGND (18.5%)

Ligand Pharmaceuticals

[1] Choosing top 10 best bets from each sector quarterly is an alpha producing strategy vs sector benchmark
[2] Historical annualized return of 11%, alpha of 1.9%, and sharpe of 0.52

Peer Outperformance in Health Care Services

ADUS has outperformed 74% of its 19 Health Care Services peers over 5Y. Among the peers that beat it is RDNT. Health Care Services ranks 3rd of 10 industries in Health Care by median 5Y return. That makes it one of the strongest corners of the sector.

Share of Health Care Services constituents that ADUS has outperformed, by holding period. Peers without a full price history over a given window are excluded from that window.

29%

of 21 industry peers · 0.0% return

47%

of 19 industry peers · 33.3% return

74%

of 19 industry peers · 35.1% return

Health Care Services peers with revenue growth within 4pp of ADUS's that beat it on at least 2 of 3 windows, and by at least 20pp over 5Y. Growth is matched by construction, so the gap is largely a re-rating gap. The multiple column is the context for it.

Ticker	Name	Rev Growth 3Y Avg	P/E	1Y	3Y	5Y	5Y Gap
ADUS	Addus HomeCare	13.9%	19.8x	0.0%	33.3%	35.1%	—
RDNT	RadNet	14.1%	-272.3x	-2.3%	167.8%	158.8%	+124pp

Price returns, excluding dividends. P/E shown for context only and not used for matching.

Median price return by industry across the Health Care sector, ranked by 5Y. Health Care Services is ADUS's own industry. Use this to see which corners of the sector have carried the returns.

Industry	Names	1Y med	3Y med	5Y med	Top 3 by 5Y
Health Care Distributors	6	19.0%	46.5%	91.6%	CAH 382% · MCK 351% · COR 171%
Managed Health Care	8	37.7%	-6.6%	0.6%	OSCR 79% · HQY 41% · ELV 14%
Health Care Services ←	20	19.1%	35.3%	-0.5%	HIMS 269% · RDNT 159% · DGX 69%
Health Care Facilities	24	5.9%	13.0%	-4.0%	NHC 269% · THC 261% · ENSG 135%
Health Care Equipment	50	-2.1%	-0.4%	-21.5%	POCI 11363% · UFPT 354% · GKOS 204%
Health Care Supplies	12	19.5%	-6.4%	-38.8%	LNTH 270% · HAE 56% · MMSI 19%
Pharmaceuticals	63	-6.9%	13.1%	-42.8%	LQDA 2369% · INDV 1106% · ETON 1024%
Life Sciences Tools & Services	113	2.5%	-8.4%	-67.1%	SNWV 1794% · MEDP 223% · NTRA 216%
Biotechnology	378	0.3%	-19.9%	-78.2%	CELZ 1243% · DNTH 1189% · TRVI 1055%
Health Care Technology	21	-24.3%	-49.3%	-78.8%	SPOK 71% · HSTM 2% · VEEV -13%

Median of constituents with a full price history over each window. Top names are unfiltered by size in this render.

Latest Trefis Analyses

	Title	Date
0	DASHBOARDS
1	Addus HomeCare Earnings Notes	12/31/2026
2	How Low Can Addus HomeCare Stock Really Go?	10/17/2025
3	ADUS Dip Buy Analysis	07/10/2025
4	Addus HomeCare (ADUS) Operating Cash Flow Comparison	02/17/2025
5	Addus HomeCare (ADUS) Net Income Comparison	02/15/2025
6	Addus HomeCare (ADUS) Operating Income Comparison	02/14/2025
7	Addus HomeCare (ADUS) Revenue Comparison	02/13/2025
8	ARTICLES
9	Better Bet Than RadNet Stock: Pay Less To Get More From ADUS	08/26/2025
10	Better Bet Than Premier Stock: Pay Less To Get More From ADUS, CHE	08/16/2025

	Title
0	DASHBOARDS
1	Addus HomeCare Earnings Notes
2	How Low Can Addus HomeCare Stock Really Go?
3	ADUS Dip Buy Analysis
4	Addus HomeCare (ADUS) Operating Cash Flow Comparison
5	Addus HomeCare (ADUS) Net Income Comparison
6	Addus HomeCare (ADUS) Operating Income Comparison
7	Addus HomeCare (ADUS) Revenue Comparison
8	ARTICLES
9	Better Bet Than RadNet Stock: Pay Less To Get More From ADUS
10	Better Bet Than Premier Stock: Pay Less To Get More From ADUS, CHE

Trade Ideas

Select ideas related to ADUS.

null

Recent Active Movers

Top Gainers

Ticker	Company	Mkt Cap (B)	1D Rtn	YTD Rtn
VKTX	Viking Therapeutics	4.7	35.7%	16.1%
MAZE	Maze Therapeutics	1.7	26.8%	-31.5%
BFLY	Butterfly Network	2.6	22.0%	161.3%
VICR	Vicor	12.3	19.8%	144.8%
BALY	Ballys	0.7	16.6%	-25.5%
SGRY	Surgery Partners	2.0	15.7%	2.3%
INOD	Innodata	2.3	14.6%	37.3%
TNGX	Tango Therapeutics	3.8	14.3%	188.1%
OMER	Omeros	1.5	13.8%	22.6%
THM	International Tower Hill Mines	0.8	12.2%	58.6%

Top Losers

Ticker	Company	Mkt Cap (B)	1D Rtn	YTD Rtn
XNDU	Xanadu Quantum Technologies	1.7	-21.6%	-49.7%
EVER	EverQuote	0.7	-14.4%	-27.6%
CLDX	Celldex Therapeutics	2.6	-11.6%	23.4%
GSHD	Goosehead Insurance	1.1	-11.5%	-37.9%
QNST	QuinStreet	0.9	-11.5%	6.3%
AESI	Atlas Energy Solutions	1.5	-9.6%	27.4%
PLNT	Planet Fitness	3.3	-9.5%	-60.7%
NKTR	Nektar Therapeutics	2.0	-8.8%	44.2%
CAR	Avis Budget	3.8	-8.1%	-16.0%
NXTT	Next Technology	0.9	-7.5%	3.6%

Top Gainers

Ticker	Company	Mkt Cap (B)	1W Rtn	YTD Rtn
SECZ	Securitize	1.9	63.1%	5.7%
VICR	Vicor	12.3	45.9%	144.8%
ALAB	Astera Labs	62.7	43.9%	118.5%
GRAL	GRAIL	4.7	43.0%	26.8%
FWDI	Forward Industries	0.7	41.4%	30.1%
GEMI	Gemini Space Station	0.7	36.6%	-40.0%
VKTX	Viking Therapeutics	4.7	36.4%	16.1%
ABSI	Absci	1.7	34.9%	206.9%
AXTI	AXT	4.8	34.8%	375.8%
SDGR	Schrodinger	2.3	32.0%	71.7%

Top Losers

Ticker	Company	Mkt Cap (B)	1W Rtn	YTD Rtn
XENE	Xenon Pharmaceuticals	3.9	-30.5%	-12.8%
XNDU	Xanadu Quantum Technologies	1.7	-25.9%	-49.7%
ALHC	Alignment Healthcare	1.7	-23.0%	-59.5%
GSHD	Goosehead Insurance	1.1	-22.9%	-37.9%
FLNC	Fluence Energy	1.0	-21.8%	-63.2%
EVER	EverQuote	0.7	-20.1%	-27.6%
RSI	Rush Street Interactive	2.4	-18.6%	9.2%
MTDR	Matador Resources	6.4	-17.9%	24.9%
SM	SM Energy	8.1	-17.8%	85.3%
CTEV	Claritev	0.5	-17.1%	-31.1%

Top Gainers

Ticker	Company	Mkt Cap (B)	1M Rtn	YTD Rtn
SECZ	Securitize	1.9	112.1%	5.7%
FWDI	Forward Industries	0.7	67.3%	30.1%
SDGR	Schrodinger	2.3	55.8%	71.7%
CAPR	Capricor Therapeutics	0.5	48.5%	-67.6%
OKTA	Okta	34.6	45.5%	127.4%
ACVA	ACV Auctions	1.8	40.6%	30.3%
SMTC	Semtech	16.2	40.5%	136.6%
MSTR	Strategy	59.0	40.3%	10.1%
GEMI	Gemini Space Station	0.7	39.0%	-40.0%
FEIM	Frequency Electronics	0.8	37.9%	58.0%

Top Losers

Ticker	Company	Mkt Cap (B)	1M Rtn	YTD Rtn
ALMS	Alumis	1.0	-66.4%	-16.9%
XNDU	Xanadu Quantum Technologies	1.7	-47.2%	-49.7%
SWMR	Swarmer	0.4	-46.7%	-26.9%
RARE	Ultragenyx Pharmaceutical	1.6	-39.5%	-32.1%
ALHC	Alignment Healthcare	1.7	-39.3%	-59.5%
KRMN	Karman	4.4	-37.3%	-54.2%
GSHD	Goosehead Insurance	1.1	-36.9%	-37.9%
FLNC	Fluence Energy	1.0	-35.9%	-63.2%
XENE	Xenon Pharmaceuticals	3.9	-35.7%	-12.8%
TTAN	ServiceTitan	5.8	-35.1%	-42.2%

Peer Comparisons

Peers to compare with:

Financials

	ADUS	ENSG	AVAH	CHE	BTSG	OPCH	Median
Name	Addus Ho.	Ensign	Aveanna .	Chemed	BrightSp.	Option C.
Mkt Price	114.24	176.32	13.22	496.62	56.55	23.90	85.39
Mkt Cap	2.1	10.2	2.9	6.5	11.7	3.7	5.1
Rev LTM	1,476	5,487	2,603	2,595	14,372	5,694	4,045
Op Inc LTM	148	467	282	352	448	334	343
FCF LTM	155	229	158	324	402	304	266
FCF 3Y Avg	116	208	82	316	205	247	206
CFO LTM	162	608	168	390	506	347	368
CFO 3Y Avg	124	464	90	372	292	288	290

Growth & Margins

	ADUS	ENSG	AVAH	CHE	BTSG	OPCH	Median
Name	Addus Ho.	Ensign	Aveanna .	Chemed	BrightSp.	Option C.
Rev Chg LTM	15.9%	18.9%	19.5%	3.3%	26.4%	5.9%	17.4%
Rev Chg 3Y Avg	13.9%	17.4%	12.5%	5.9%	21.9%	11.4%	13.2%
Rev Chg Q	8.0%	17.3%	13.7%	8.8%	23.0%	1.9%	11.3%
QoQ Delta Rev Chg LTM	1.9%	4.0%	3.2%	2.1%	5.3%	0.5%	2.7%
Op Inc Chg LTM	27.5%	18.2%	30.1%	-4.7%	143.5%	-0.1%	22.8%
Op Inc Chg 3Y Avg	23.8%	17.9%	69.4%	4.9%	164.0%	6.4%	20.8%
Op Mgn LTM	10.0%	8.5%	10.8%	13.6%	3.1%	5.9%	9.3%
Op Mgn 3Y Avg	9.4%	8.0%	8.9%	14.6%	1.4%	6.3%	8.5%
QoQ Delta Op Mgn LTM	0.2%	0.0%	-0.3%	0.5%	0.4%	0.0%	0.1%
CFO/Rev LTM	11.0%	11.1%	6.5%	15.0%	3.5%	6.1%	8.7%
CFO/Rev 3Y Avg	9.6%	9.7%	3.7%	14.9%	2.4%	5.5%	7.5%
FCF/Rev LTM	10.5%	4.2%	6.1%	12.5%	2.8%	5.3%	5.7%
FCF/Rev 3Y Avg	8.9%	4.5%	3.4%	12.7%	1.6%	4.7%	4.6%

Valuation

	ADUS	ENSG	AVAH	CHE	BTSG	OPCH	Median
Name	Addus Ho.	Ensign	Aveanna .	Chemed	BrightSp.	Option C.
Mkt Cap	2.1	10.2	2.9	6.5	11.7	3.7	5.1
P/S	1.4	1.9	1.1	2.5	0.8	0.6	1.3
P/Op Inc	14.1	21.9	10.2	18.6	26.0	11.0	16.3
P/EBIT	13.9	20.2	10.4	17.6	26.0	10.8	15.7
P/E	19.8	27.0	10.5	23.8	31.8	17.4	21.8
P/CFO	12.9	16.8	17.1	16.8	23.0	10.5	16.8
Total Yield	5.0%	3.9%	9.5%	4.7%	3.1%	5.7%	4.9%
Dividend Yield	0.0%	0.1%	0.0%	0.5%	0.0%	0.0%	0.0%
FCF Yield 3Y Avg	6.1%	2.5%	6.0%	4.5%	2.6%	6.0%	5.2%
D/E	0.1	0.2	0.5	0.0	0.2	0.3	0.2
Net D/E	0.0	0.2	0.5	0.0	0.2	0.3	0.2

Returns

	ADUS	ENSG	AVAH	CHE	BTSG	OPCH	Median
Name	Addus Ho.	Ensign	Aveanna .	Chemed	BrightSp.	Option C.
1M Rtn	-5.4%	-1.8%	0.5%	-8.1%	-3.9%	0.8%	-2.9%
3M Rtn	18.9%	11.0%	61.2%	12.0%	-15.4%	8.8%	11.5%
6M Rtn	15.0%	-13.0%	100.0%	33.2%	30.6%	-15.9%	22.8%
12M Rtn	0.0%	5.9%	57.4%	9.5%	104.9%	-16.6%	7.7%
3Y Rtn	33.3%	89.4%	966.1%	-1.8%	414.1%	-28.2%	61.3%
1M Excs Rtn	-6.6%	-2.9%	-0.7%	-9.3%	-5.1%	-0.3%	-4.0%
3M Excs Rtn	13.5%	5.6%	55.8%	6.6%	-20.8%	3.4%	6.1%
6M Excs Rtn	-3.5%	-30.8%	79.0%	15.4%	16.3%	-33.9%	5.9%
12M Excs Rtn	-14.4%	-9.0%	46.7%	-6.1%	90.6%	-32.1%	-7.6%
3Y Excs Rtn	-37.9%	16.2%	769.8%	-76.3%	339.6%	-105.9%	-10.8%

Comparison Analyses

	Title
0	ADUS Could Deliver 48% Returns And Outperform SLP
1	ADUS Could Deliver 48% Returns And Outperform AMED
2	Addus HomeCare vs. Guidewire Software: With Return Forecast Of 65%, Guidewire Software Is A Better Bet
3	Addus HomeCare vs. Penumbra: With Return Forecast Of 89%, Penumbra Is A Better Bet
4	Addus HomeCare vs. ABIOMED: With Return Forecast Of 76%, ABIOMED Is A Better Bet
5	Addus HomeCare vs. G-III Apparel: Similar Market Cap, But Addus HomeCare Is A Better Bet
6	Addus HomeCare vs. GoPro: Similar Market Cap, But Addus HomeCare Is A Better Bet
7	Addus HomeCare vs. Innoviva: Similar Market Cap, But Addus HomeCare Is A Better Bet
8	Addus HomeCare vs Inovio Pharmaceuticals: Similar Market Cap; Which Stock Is A Better Bet?
9	Addus HomeCare vs REGENXBIO: Similar Market Cap; Which Stock Is A Better Bet?

FDIC Bank Data

Bank Capital

null

Bank Deposits

null

Bank Assets

null

Bank Loans

null

FDA Approved Drugs Data

Expand for Morenull

Clinical Pipeline

null

Financials

Annual
Quarterly

$ Mil \| FY: 12/31	LTM	2025	2024	2023	2022	2021	2020
Period End	6/30/2026	12/31/2025	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020
Filing Date	8/4/2026	2/24/2026	2/25/2025	2/27/2024	2/28/2023	2/25/2022	3/1/2021
Key Financials
Total Revenue	1,476	1,423	1,155	1,059	951	864	765
Gross Profit	478	462	375	340	300	270	226
EBITDA	167	157	121	107	83	81	57
Operating Income	148	139	103	91	69	66	45
Net Income	105	96	74	63	46	45	33
EPS	5.76	5.31	4.33	3.91	2.90	2.87	2.12
Growth Rates
Total Revenue Growth	15.9%	23.2%	9.1%	11.3%	10.0%	13.0%	17.9%
EBITDA Growth	23.6%	30.6%	13.2%	28.2%	3.0%	41.1%	22.1%
Operating Income Growth	27.5%	35.0%	12.9%	32.3%	4.2%	48.1%	28.1%
Net Income Growth	26.9%	30.3%	17.7%	35.8%	2.0%	36.2%	31.3%
Margins
Gross Margin	32.4%	32.5%	32.5%	32.1%	31.5%	31.2%	29.6%
EBITDA Margin	11.3%	11.1%	10.4%	10.1%	8.7%	9.3%	7.5%
Operating Income Margin	10.0%	9.7%	8.9%	8.6%	7.2%	7.6%	5.8%
Net Income Margin	7.1%	6.7%	6.4%	5.9%	4.8%	5.2%	4.3%
Cash & Debt
Total Cash	100	82	99	65	80	169	145
Total Debt	109	171	273	175	178	264	240
Net Debt / (Cash)	9	90	174	110	98	95	95
Cash Flows & CapEx
Net Cash from Operations	162	112	116	112	105	39	109
Total CapEx	-8	-8	-6	-9	-8	-5	-7
Free Cash from Operations	155	104	110	103	97	35	103
Returns to Shareholders
Dividends	0	-0	-0	-0	-0	-0	-0
Share Repurchases	-0	-0	-0	-0	-0	-0	-0

$ Mil \| FY: 12/31	2026Q2	2026Q1	2025Q4	2025Q3	2025Q2	2025Q1	2024Q4	2024Q3	2024Q2	2024Q1	2023Q4	2023Q3
Period End	6/30/2026	3/31/2026	12/31/2025	9/30/2025	6/30/2025	3/31/2025	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023
Filing Date	8/4/2026	5/5/2026	2/24/2026	11/4/2025	8/5/2025	5/6/2025	2/25/2025	11/5/2024	8/6/2024	5/7/2024	2/27/2024	10/31/2023
Key Financials Quarterly
Total Revenue	377	364	373	362	349	338	297	290	287	281	276	271
Ebitda	44	39	47	38	37	35	32	31	30	28	32	27
Operating Income	39	34	42	33	33	31	27	26	26	24	28	23
Net Income	28	25	30	23	22	21	20	20	18	16	20	15
EPS	1.51	1.38	1.61	1.26	1.22	1.18	1.08	1.13	1.12	0.99	1.21	0.96
Key Financials TTM
Total Revenue TTM	1,476	1,448	1,423	1,347	1,274	1,212	1,155	1,134	1,115	1,088	1,059	1,029
Ebitda TTM	167	161	157	142	135	128	121	121	117	112	107	99
Operating Income TTM	148	142	139	123	116	110	103	104	101	96	91	84
Net Income TTM	105	100	96	86	83	79	74	74	69	66	63	58
Growth Rates Quarterly
Total Revenue Growth	8.0%	7.7%	25.6%	25.0%	21.8%	20.3%	7.5%	7.0%	10.4%	11.6%	11.9%	12.6%
EBITDA Growth	16.7%	10.4%	48.3%	21.7%	24.4%	27.0%	-1.3%	15.8%	19.2%	24.3%	31.8%	28.5%
Operating Income Growth	18.4%	11.7%	57.1%	26.9%	25.6%	29.1%	-3.8%	13.6%	21.6%	27.1%	34.4%	30.4%
Net Income Growth	25.2%	18.1%	52.5%	13.3%	22.0%	34.1%	-0.3%	30.8%	21.7%	24.9%	32.6%	33.5%
Margins Quarterly
EBITDA Margin	11.6%	10.6%	12.6%	10.5%	10.7%	10.4%	10.7%	10.8%	10.5%	9.8%	11.6%	10.0%
Operating Income Margin	10.3%	9.4%	11.3%	9.1%	9.4%	9.0%	9.1%	9.0%	9.1%	8.4%	10.1%	8.4%
Net Income Margin	7.3%	6.9%	8.0%	6.3%	6.3%	6.3%	6.6%	7.0%	6.3%	5.6%	7.1%	5.7%
Cash & Debt
Total Cash	100	103	82	102	91	97	99	223	173	77	65	80
Total Debt	109	139	171	202	222	251	273	50	50	150	175	217
Net Debt / (Cash)	9	36	90	101	131	154	174	-173	-124	73	110	137
Cash Flows Quarterly
FCF from Operations	40	52	19	51	23	19	10	49	19	39	30	22
Cash Flows TTM
FCF from Operations TTM	162	145	112	103	100	97	116	136	109	132	112	106
Returns to Shareholders Quarterly
Dividends	0	0	0	0	0	0	0	0	0	0	0	0
Share Repurchases	-0	-0	-0	-0	-0	-0	-0	-0	-0	-0	-0	-0
Return on Invested Capital (ROIC) Quarterly
ROIC	18.0%	16.1%	17.9%	14.0%	13.2%	12.8%	10.4%	18.4%	16.7%	14.7%	16.8%	12.9%
Return on Invested Capital (ROIC) TTM
ROIC TTM	17.5%	16.3%	14.8%	13.1%	11.9%	11.0%	9.9%	18.6%	16.4%	15.2%	13.6%	12.1%

Segment Financials

Revenue by Segment

$ Mil	2025	2024	2023	2022	2021
Personal Care	1,089	857	795	707	686
Hospice	263	228	207	202	152
Home Health	71	70	57	43	26
Total	1,423	1,155	1,059	951	864

Operating Income by Segment

$ Mil	2025	2024	2023	2022	2021
Personal Care	207	174	158	125	122
Hospice	67	52	45	51	42
Home Health	12	8	7	3	3
Depreciation and amortization	-16	-14	-14	-14	-14
Other general and administrative expenses	-132	-118	-104	-96	-88
Total	139	103	91	69	66

Assets by Segment

$ Mil	2011	2010	2009	2008
Home & Community	118	122	118	91
Corporate	23	16		20
Home Health	14	29	27	24
General corporate expenses & corporate depreciation			16
Total	155	167	161	136

Price Behavior

Price Behavior

Market Price	$114.24
Market Cap ($ Bil)	2.1
First Trading Date	10/28/2009
Distance from 52W High	-6.9%
	50 Days	200 Days
DMA Price	$116.70	$105.68
DMA Trend	indeterminate	up
Distance from DMA	-2.1%	8.1%
	3M	1YR
Volatility	24.4%	29.1%
Downside Capture	-40.39	34.84
Upside Capture	54.95	28.43
Correlation (SPY)	-11.2%	11.0%

ADUS Betas & Captures as of 8/31/2026

	1M	2M	3M	6M	1Y	3Y
Beta	-0.56	-0.37	-0.19	0.11	0.27	0.51
Up Beta	-1.16	-1.44	-0.41	-0.31	0.00	0.48
Down Beta	-1.61	-0.70	-0.50	0.27	0.34	0.19
Up Capture	-12%	57%	51%	25%	20%	37%
Bmk +ve Days	10	21	32	68	138	427
Stock +ve Days	11	25	40	68	126	380
Down Capture	-2%	-42%	-65%	14%	45%	89%
Bmk -ve Days	11	21	32	59	113	324
Stock -ve Days	10	17	24	59	123	366

[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively

Based On 1-Year Data

	Annualized Return	Annualized Volatility	Sharpe Ratio	Correlation with ADUS
ADUS	2.1%	29.1%	0.07	-
Sector ETF (XLV)	26.0%	16.1%	1.24	27.4%
Equity (SPY)	17.6%	13.0%	0.98	11.0%
Gold (GLD)	18.0%	29.3%	0.56	6.7%
Commodities (DBC)	46.6%	20.7%	1.75	-8.5%
Real Estate (VNQ)	5.2%	13.6%	0.12	17.3%
Bitcoin (BTCUSD)	-26.0%	44.9%	-0.54	7.2%

Smart multi-asset allocation framework can stack odds in your favor. Learn How

Based On 5-Year Data

	Annualized Return	Annualized Volatility	Sharpe Ratio	Correlation with ADUS
ADUS	5.9%	34.2%	0.23	-
Sector ETF (XLV)	6.8%	15.2%	0.26	33.0%
Equity (SPY)	13.3%	17.2%	0.59	32.0%
Gold (GLD)	18.9%	18.8%	0.81	4.0%
Commodities (DBC)	10.8%	19.6%	0.43	0.3%
Real Estate (VNQ)	1.0%	18.9%	-0.05	28.2%
Bitcoin (BTCUSD)	12.7%	52.6%	0.42	16.8%

Smart multi-asset allocation framework can stack odds in your favor. Learn How

Based On 10-Year Data

	Annualized Return	Annualized Volatility	Sharpe Ratio	Correlation with ADUS
ADUS	16.5%	38.8%	0.51	-
Sector ETF (XLV)	10.8%	16.7%	0.52	35.0%
Equity (SPY)	15.4%	17.9%	0.73	33.9%
Gold (GLD)	12.2%	16.4%	0.61	5.0%
Commodities (DBC)	8.3%	18.1%	0.37	7.8%
Real Estate (VNQ)	4.7%	20.7%	0.19	27.5%
Bitcoin (BTCUSD)	64.0%	66.2%	1.04	9.7%

Smart multi-asset allocation framework can stack odds in your favor. Learn How

Short Interest

Short Interest: As Of Date	8312026
Short Interest: Shares Quantity	0.9 Mil
Short Interest: % Change Since 8152026	-11.6%
Average Daily Volume	0.2 Mil
Days-to-Cover Short Interest	4.8 days
Basic Shares Quantity	18.3 Mil
Short % of Basic Shares	4.9%

Returns Analyses

	Title
0	How Low Can Addus HomeCare Stock Really Go?
1	Addus HomeCare Stock Return Comparison
2	Addus HomeCare Total Shareholder Return (TSR): 6.4% in 2022 and 0.8% 3-yr returns (above peer average)
3	Addus HomeCare (ADUS) Stock Return: AI Predicts ADUS Average and Excess Return After a Fall or Rise

Earnings Returns History

Updated 9/14/2026

Expand for More

	Forward Returns
Earnings Date	1D Returns	5D Returns	21D Returns
8/3/2026	-2.7%	2.2%	-1.9%
5/4/2026	-1.7%	-2.3%	-11.6%
2/23/2026	-10.6%	-10.5%	-15.6%
11/3/2025	-5.7%	-5.2%	-4.1%
8/4/2025	9.0%	4.7%	5.7%
5/5/2025	4.1%	5.9%	7.3%
2/24/2025	-10.4%	-12.7%	-12.7%
11/4/2024	-3.7%	-0.8%	-4.2%
...
SUMMARY STATS
# Positive	12	13	11
# Negative	12	11	13
Median Positive	5.9%	6.6%	7.3%
Median Negative	-4.4%	-5.8%	-5.0%
Max Positive	12.9%	13.0%	17.4%
Max Negative	-10.6%	-17.9%	-15.6%

Collapse to Preview

	Forward Returns
Earnings Date	1D Returns	5D Returns	21D Returns
8/3/2026	-2.7%	2.2%	-1.9%
5/4/2026	-1.7%	-2.3%	-11.6%
2/23/2026	-10.6%	-10.5%	-15.6%
11/3/2025	-5.7%	-5.2%	-4.1%
8/4/2025	9.0%	4.7%	5.7%
5/5/2025	4.1%	5.9%	7.3%
2/24/2025	-10.4%	-12.7%	-12.7%
11/4/2024	-3.7%	-0.8%	-4.2%
8/5/2024	5.8%	6.6%	10.9%
5/6/2024	6.8%	13.0%	17.2%
2/26/2024	5.5%	9.6%	17.4%
10/30/2023	-5.2%	2.0%	5.4%
7/31/2023	1.5%	2.9%	-2.5%
5/1/2023	-2.6%	-5.8%	1.5%
2/27/2023	2.6%	-2.2%	-1.5%
10/31/2022	6.0%	7.2%	7.7%
8/1/2022	0.5%	-1.9%	-7.1%
5/3/2022	-2.3%	-7.0%	-4.2%
2/24/2022	12.9%	7.0%	8.5%
11/1/2021	-3.1%	8.0%	-11.2%
8/3/2021	11.3%	9.3%	5.7%
5/3/2021	-5.9%	-8.3%	-9.3%
2/25/2021	-5.0%	-17.9%	-5.0%
11/3/2020	8.0%	0.4%	0.9%
SUMMARY STATS
# Positive	12	13	11
# Negative	12	11	13
Median Positive	5.9%	6.6%	7.3%
Median Negative	-4.4%	-5.8%	-5.0%
Max Positive	12.9%	13.0%	17.4%
Max Negative	-10.6%	-17.9%	-15.6%

SEC Filings

Expand for More

Report Date	Filing Date	Filing
06/30/2026	08/04/2026	10-Q
03/31/2026	05/05/2026	10-Q
12/31/2025	02/24/2026	10-K
09/30/2025	11/04/2025	10-Q
06/30/2025	08/05/2025	10-Q
03/31/2025	05/06/2025	10-Q
12/31/2024	02/25/2025	10-K
09/30/2024	11/05/2024	10-Q
06/30/2024	08/06/2024	10-Q
03/31/2024	05/07/2024	10-Q
12/31/2023	02/27/2024	10-K
09/30/2023	10/31/2023	10-Q
06/30/2023	08/01/2023	10-Q
03/31/2023	05/02/2023	10-Q
12/31/2022	02/28/2023	10-K
09/30/2022	11/01/2022	10-Q

Collapse to Preview

Report Date	Filing Date	Filing
06/30/2026	08/04/2026	10-Q
03/31/2026	05/05/2026	10-Q
12/31/2025	02/24/2026	10-K
09/30/2025	11/04/2025	10-Q
06/30/2025	08/05/2025	10-Q
03/31/2025	05/06/2025	10-Q
12/31/2024	02/25/2025	10-K
09/30/2024	11/05/2024	10-Q
06/30/2024	08/06/2024	10-Q
03/31/2024	05/07/2024	10-Q
12/31/2023	02/27/2024	10-K
09/30/2023	10/31/2023	10-Q
06/30/2023	08/01/2023	10-Q
03/31/2023	05/02/2023	10-Q
12/31/2022	02/28/2023	10-K
09/30/2022	11/01/2022	10-Q
06/30/2022	08/02/2022	10-Q
03/31/2022	05/03/2022	10-Q
12/31/2021	02/25/2022	10-K
09/30/2021	11/02/2021	10-Q
06/30/2021	08/04/2021	10-Q
03/31/2021	05/07/2021	10-Q
12/31/2020	03/01/2021	10-K
09/30/2020	11/06/2020	10-Q
06/30/2020	08/10/2020	10-Q
03/31/2020	08/10/2020	10-Q
12/31/2019	08/10/2020	10-K
09/30/2019	11/08/2019	10-Q

Recent Forward Guidance

Updated 8/4/2026

Latest: Q2 2026 Earnings Reported 8/3/2026

null

Prior: Q4 2025 Earnings Reported 2/23/2026

Forward Guidance					Guidance Change
Metric	Source	Low	Mid	High	% Chg	% Delta	Change	Prior
2026 Rate Increase	Reported		0.04

Insider Activity

Updated 6/23/2026

Expand for More

#	Owner	Title	Holding	Action	Filing Date	Price	Shares	Transacted Value	Value of Held Shares	Form
1	Dixon, Heather Brianne	President and Chief Operating	Direct	Sell	6232026	93.77	288	27,006	4,160,669	Form
2	Lopez, Esteban		Direct	Sell	5222026	93.00	250	23,250	297,600	Form
3	Lopez, Esteban		Direct	Sell	5212026	93.00	250	23,250	320,850	Form
4	Blessing, Cliff Donald	EVP, Chief Development Officer	Direct	Sell	4222026	93.61	178	16,663	1,140,451	Form
5	Raines, Monica	EVP, CCO and Quality Officer	Direct	Sell	3032026	102.15	224	22,882	1,386,891	Form

Collapse to Preview

#	Owner	Title	Holding	Action	Filing Date	Price	Shares	Transacted Value	Value of Held Shares	Form
1	Dixon, Heather Brianne	President and Chief Operating	Direct	Sell	6232026	93.77	288	27,006	4,160,669	Form
2	Lopez, Esteban		Direct	Sell	5222026	93.00	250	23,250	297,600	Form
3	Lopez, Esteban		Direct	Sell	5212026	93.00	250	23,250	320,850	Form
4	Blessing, Cliff Donald	EVP, Chief Development Officer	Direct	Sell	4222026	93.61	178	16,663	1,140,451	Form
5	Raines, Monica	EVP, CCO and Quality Officer	Direct	Sell	3032026	102.15	224	22,882	1,386,891	Form
6	Raines, Monica	EVP, CCO and Quality Officer	Direct	Sell	2262026	105.36	219	23,074	1,454,073	Form
7	Stevenson, Roberton James	EVP, Chief HR Officer	Direct	Sell	2262026	105.36	284	29,922	1,478,201	Form
8	Blessing, Cliff Donald	EVP, Chief Development Officer	Direct	Sell	2262026	105.36	177	18,649	1,302,355	Form
9	Wattenbarger, Michael D	EVP, Chief Information Officer	Direct	Sell	2262026	105.36	300	31,608	995,020	Form
10	Tucker, David W	EVP, Chief Strategy Officer	Direct	Sell	2262026	105.36	379	39,931	1,098,167	Form
11	Anderson, Darby	EVP, Chief Govt Rel Officer	Direct	Sell	2262026	105.36	396	41,723	4,872,479	Form
12	Gaffney, Sean	EVP, Chief Legal Officer	Direct	Sell	2262026	105.36	442	46,569	2,115,629	Form
13	Poff, Brian	EVP, Chief Financial Officer	Direct	Sell	2262026	105.36	820	86,395	6,710,589	Form
14	Allison, R Dirk	Chairman and CEO	Direct	Sell	2262026	105.36	2,364	249,071	19,296,684	Form
15	Raines, Monica	EVP, CCO and Quality Officer	Direct	Sell	2262026	106.99	437	46,755	1,500,000	Form
16	Stevenson, Roberton James	EVP, Chief HR Officer	Direct	Sell	2262026	107.35	567	60,867	1,536,608	Form
17	Blessing, Cliff Donald	EVP, Chief Development Officer	Direct	Sell	2262026	107.14	350	37,499	1,343,321	Form
18	Wattenbarger, Michael D	EVP, Chief Information Officer	Direct	Sell	2262026	107.35	592	63,551	1,046,018	Form
19	Tucker, David W	EVP, Chief Strategy Officer	Direct	Sell	2262026	107.35	704	75,574	1,159,595	Form
20	Anderson, Darby	EVP, Chief Govt Rel Officer	Direct	Sell	2262026	106.98	733	78,416	4,989,761	Form
21	Gaffney, Sean	EVP, Chief Legal Officer	Direct	Sell	2262026	106.98	817	87,403	2,195,444	Form
22	Poff, Brian	EVP, Chief Financial Officer	Direct	Sell	2262026	106.98	2,041	218,346	6,901,494	Form
23	Allison, R Dirk	Chairman and CEO	Direct	Sell	2262026	106.98	4,988	533,616	19,846,288	Form
24	Raines, Monica	EVP, CCO and Quality Officer	Direct	Sell	2242026	114.91	446	51,250	1,661,254	Form
25	Stevenson, Roberton James	EVP, Chief HR Officer	Direct	Sell	2242026	114.91	561	64,465	1,709,976	Form
26	Blessing, Cliff Donald	EVP, Chief Development Officer	Direct	Sell	2242026	114.91	371	42,632	1,480,960	Form
27	Wattenbarger, Michael D	EVP, Chief Information Officer	Direct	Sell	2242026	114.91	577	66,303	1,187,710	Form
28	Tucker, David W	EVP, Chief Strategy Officer	Direct	Sell	2242026	114.91	658	75,611	1,322,154	Form
29	Anderson, Darby	EVP, Chief Govt Rel Officer	Direct	Sell	2242026	114.91	666	76,530	5,443,861	Form
30	Gaffney, Sean	EVP, Chief Legal Officer	Direct	Sell	2242026	114.91	737	84,689	2,452,064	Form
31	Poff, Brian	EVP, Chief Financial Officer	Direct	Sell	2242026	114.91	1,858	213,503	7,647,605	Form
32	Allison, R Dirk	Chairman and CEO	Direct	Sell	2242026	114.91	4,535	521,117	21,890,585	Form
33	Lopez, Esteban		Direct	Sell	12162025	115.18	150	17,278	426,178	Form
34	Lopez, Esteban		Direct	Sell	12082025	112.78	166	18,721	434,203	Form
35	Anderson, Darby	EVP, Chief Govt Rel Officer	Direct	Sell	11202025	109.00	20,000	2,180,000	4,811,696	Form
36	Bickham, W Bradley	President and COO	Direct	Sell	9032025	115.75	4,000	463,000	4,352,779	Form
37	Allison, R Dirk	Chairman and CEO	Direct	Sell	9032025	115.83	25,000	2,895,750	19,281,176	Form
38	Poff, Brian	EVP, Chief Financial Officer	Direct	Sell	8262025	116.82	7,739	904,088	6,656,533	Form
39	Allison, R Dirk	Chairman and CEO	Direct	Sell	8212025	114.95	25,000	2,873,851	19,135,363	Form
40	Hill-Milbourne, Veronica		Direct	Sell	8212025	114.93	1,571	180,555	582,350	Form
41	Bickham, W Bradley	President and COO	Direct	Sell	8152025	115.34	9,000	1,038,100	4,902,716	Form
42	Lopez, Esteban		Direct	Sell	8112025	109.00	522	56,898	437,744	Form
43	Stevenson, Roberton James	EVP & Chief HR Officer	Direct	Sell	6172025	112.99	228	25,762	1,421,866	Form
44	Tucker, David W	EVP / Chief Strategy Officer	Direct	Sell	6122025	115.43	2,403	277,378	1,008,281	Form

Investor Activity (13F)

Updated

13F holdings as of

ADUS Trade Sentinel

Stock Conviction

null

CONVICTION RATIONALE

null

STOCK ARCHETYPE

null

Looking for high-conviction positions with a better risk/reward profile? See what's currently in the Trefis High Quality Portfolio.

INVESTMENT THESIS

null

Mechanism: null

Supporting Evidence:

PRIMARY RISK

null

Mechanism: null

Supporting Evidence:

Key KPI Watchlist

KPI	Status	Rationale

Core Investment Debate

BULL VIEW

CORE TENSION

PREVAILING SENTIMENT

BEAR VIEW

Next 6 months: Risks and Catalysts

Timeline	Event & Metric To Watch

Key Events in Last 6 Months

Date	Event	Stock Impact

Risk Management

Position Sizing

Diversification Alternatives

How Is The Market Pricing ADUS?

What will confirm the thesis

What will damage the thesis

Noise: Real but irrelevant to thesis

Repricing Catalyst

What ADUS Makes & Who Pays

TTM figures based on

ADUS Evolution: Price Return by Era

① Structure

② Volume / Momentum

③ Catalyst

Combined Score

0 / 12

1 Price Structure & Trend · ▾

2 Momentum ▾

3 Relative Strength vs. SPY ▾

4 Institutional Footprint & Volume ▾

5 Volatility ▾

6 Key Price Levels Range · Vol ▾

7 Earnings Reaction History ▾

8 How the Verdict Is Derived Three Pillars ▾

Pillar	Score
① Structure	0
② Vol / Mom	0
③ Catalyst	0

ℹ Bull Pillars: 0 · Bear Pillars: 0 · Combined Score: 0 →

Industry Resources

Health Care Resources

U.S. National Library of Medicine

Health Data Management

FDA Tracker

Health Care Services Resources

HealthLeaders Media

Medical Economics

Physicians Practice

External Quote Links

0	Y Finance	Barrons
1	TradingView	Morningstar
2	SeekingAlpha	ValueLine
3	Motley Fool	Robinhood
4	CNBC	Etrade
5	MarketWatch	Unusual Whales
6	YCharts	Perplexity Finance
7	FinViz

Prefer one of these to Trefis? Tell us why.

Core Cache Last Updated: 9/22/2026

Addus HomeCare (ADUS)

Market Price (9/23/2026): $114.1 | Market Cap: $2.1 BilSector: Health Care | Industry: Health Care Services

Addus HomeCare (ADUS)

Market Price (9/23/2026): $114.1Market Cap: $2.1 BilSector: Health CareIndustry: Health Care Services

Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.

ADUS in ETFs

Valuation & Metrics

Price Chart

Why The Stock Moved

Qualitative Assessment

Stock Movement Drivers

Fundamental Drivers

Market Drivers

Fundamental Drivers

Market Drivers

Fundamental Drivers

Market Drivers

Fundamental Drivers

Market Drivers

Return vs. Risk

Price Returns Compared

How Low Can It Go

In The Past

Preserve Wealth

Asset Allocation

In The Past

Preserve Wealth

Asset Allocation

About Addus HomeCare (ADUS)

Share Repurchases

Share Issuance

Outbound Investments

Capital Expenditures

Interactive Breakdown

Better Bets vs. Addus HomeCare (ADUS)

INDUSTRY: Health Care Services

Higher Rev Chg 3Y Avg | Lower P/S (Values for ADUS: 13.9% | 1.4x)

Higher Rev Chg 3Y Avg | Lower P/Op Inc (Values for ADUS: 13.9% | 14.1x)

Higher Rev Chg LTM (Value for ADUS: 15.9%)

Higher Rev Chg 3Y Avg (Value for ADUS: 13.9%)

Higher Op Mgn LTM (Value for ADUS: 10.0%)

Higher CFO/Rev LTM (Value for ADUS: 11.0%)

Higher FCF/Rev LTM (Value for ADUS: 10.5%)

Higher Total Yield (Value for ADUS: 5.0%)

SECTOR: Health Care

Higher Rev Chg 3Y Avg | Lower P/S (Values for ADUS: 13.9% | 1.4x)

Higher Rev Chg 3Y Avg | Lower P/Op Inc (Values for ADUS: 13.9% | 14.1x)

Higher Rev Chg LTM (Value for ADUS: 15.9%)

Higher Rev Chg 3Y Avg (Value for ADUS: 13.9%)

Higher Op Mgn LTM (Value for ADUS: 10.0%)

Higher CFO/Rev LTM (Value for ADUS: 11.0%)

Higher FCF/Rev LTM (Value for ADUS: 10.5%)

Higher Total Yield (Value for ADUS: 5.0%)

All Other Sectors

Higher Rev Chg 3Y Avg | Lower P/S (Values for ADUS: 13.9% | 1.4x)

Higher Rev Chg 3Y Avg | Lower P/Op Inc (Values for ADUS: 13.9% | 14.1x)

Higher Rev Chg LTM (Value for ADUS: 15.9%)

Higher Rev Chg 3Y Avg (Value for ADUS: 13.9%)

Higher Op Mgn LTM (Value for ADUS: 10.0%)

Higher CFO/Rev LTM (Value for ADUS: 11.0%)

Higher FCF/Rev LTM (Value for ADUS: 10.5%)

Higher Total Yield (Value for ADUS: 5.0%)

Best Bets in Health Care

P/EBIT (Value for ADUS: 13.9x)

P/E (Value for ADUS: 19.8x)

Rev Chg 3Y Avg (Value for ADUS: 13.9%)

Rev Chg LTM (Value for ADUS: 15.9%)

Rev Chg Q (Value for ADUS: 8.0%)

FCF/Rev 3Y Avg (Value for ADUS: 8.9%)

Peer Outperformance in Health Care Services

Latest Trefis Analyses

Trade Ideas

Recent Active Movers

Top Gainers

Top Losers

Top Gainers

Top Losers

Top Gainers

Top Losers

More From Trefis

Market Price (9/23/2026): $114.1
Market Cap: $2.1 Bil
Sector: Health Care
Industry: Health Care Services